Viridian Therapeutics (VRDN)
NASDAQ:VRDN
Top Page
Viridian Therapeutics
(NASDAQ:VRDN)
Select Model
Select Model
Rating:54Neutral
Price Target:
$15.00
▲(3.66% Upside)
Action:ReiteratedDate:03/31/26
The score is driven by a strong balance sheet and a major positive Phase 3 readout, partially offset by very weak profitability and heavy cash burn. Technicals also remain soft with the stock below key moving averages and negative MACD, while valuation is constrained by losses and no dividend support.
Positive Factors
Conservative balance sheet with no debt
Zero reported debt and a sizable equity base provide structural financial flexibility. This lowers refinancing risk and gives management capacity to fund late-stage regulatory activities, potential initial commercialization and operating losses over the next 2-6 months without immediate liquidity pressure.
Negative Factors
High cash burn and negative operating cash flow
Sustained, large negative operating and free cash flow is a persistent structural risk. Continued burn will necessitate financing or rapid commercial scaling, pressuring dilution or forcing budget cuts that could impair R&D/commercial execution over the medium term if revenues don't accelerate.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet with no debt
Zero reported debt and a sizable equity base provide structural financial flexibility. This lowers refinancing risk and gives management capacity to fund late-stage regulatory activities, potential initial commercialization and operating losses over the next 2-6 months without immediate liquidity pressure.
Read all positive factors
Viridian Therapeutics (VRDN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.48B
Dividend YieldN/A
Average Volume (3M)814.59K
Price to Earnings (P/E)―
Beta (1Y)1.04
Revenue Growth23340.07%
EPS Growth18.06%
CountryUS
Employees143
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.08
Shares Outstanding102,206,570
10 Day Avg. Volume1,087,693
30 Day Avg. Volume814,586
Financial Highlights & Ratios
PEG Ratio0.46
Price to Book (P/B)3.65
Price to Sales (P/S)37.25
P/FCF Ratio-9.53
Enterprise Value/Market Cap0.72
Enterprise Value/Revenue15.05
Enterprise Value/Gross Profit15.12
Enterprise Value/Ebitda-3.19
Forecast
1Y Price Target
$33.33Price Target Upside130.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-3.82
Revenue Forecast (FY)$73.40M
Viridian Therapeutics Business Overview & Revenue Model
Company Description
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyr...
How the Company Makes Money
null...
Viridian Therapeutics Earnings Call Summary
Earnings Call Date:May 08, 2024
(Q1-2024)
| % Change Since: |
Next Earnings Date:May 12, 2026
Earnings Call Sentiment Positive
The earnings call reflects significant progress and positive developments in the company's pipeline, particularly with the completion of enrollment in the THRIVE trial, a strong financial position, and positive regulatory interactions. However, there are challenges, such as the extended timeline for BLA submission and concerns about hearing impairment assessments in clinical trials.Positive Updates
Completion of THRIVE Phase III Enrollment
The THRIVE Phase III trial evaluating 001 in patients with active TED completed enrollment ahead of schedule with 113 patients, exceeding the target of 90 due to strong patient demand.
Negative Updates
Extended Timeline for BLA Submission
The BLA submission for the 001 program is anticipated in the second half of 2025, driven primarily by the extended follow-up period in the THRIVE 2 trial.
Read all updates
Q1-2024 Updates
Positive
Negative
Completion of THRIVE Phase III Enrollment
The THRIVE Phase III trial evaluating 001 in patients with active TED completed enrollment ahead of schedule with 113 patients, exceeding the target of 90 due to strong patient demand.
Read all positive updates
Company Guidance
During Viridian Therapeutics' Q1 2024 earnings call, the company provided several updates on their pipeline and financial outlook. Viridian announced the completion of enrollment for their THRIVE Phase III trial for the 001 IV program, surpassing the target with 113 patients. They anticipate top-line results in September 2024 and plan a BLA submission for the 001 program in the second half of 2025. The company also highlighted progress in their FcRn portfolio, with an IND for 006 expected by the end of 2024 and 008 nonhuman primate data anticipated in the second half of 2024. Viridian ended the quarter with $613 million in cash, cash equivalents, and short-term investments, maintaining a cash runway into the second half of 2026.Viridian Therapeutics Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
76
Positive
Cash Flow
28
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 70.85M | 302.00K | 314.00K | 1.77M | 2.96M |
| Gross Profit | 69.69M | 302.00K | 314.00K | 1.77M | 2.96M |
| EBITDA | -337.65M | -265.66M | -235.37M | -129.13M | -79.29M |
| Net Income | -342.60M | -269.95M | -237.73M | -129.87M | -79.41M |
Balance Sheet | |||||
| Total Assets | 899.42M | 742.40M | 490.42M | 435.09M | 203.71M |
| Cash, Cash Equivalents and Short-Term Investments | 874.65M | 717.58M | 477.37M | 424.55M | 196.97M |
| Total Debt | 50.69M | 21.09M | 21.05M | 5.26M | 520.00K |
| Total Liabilities | 177.25M | 70.76M | 48.40M | 40.03M | 15.99M |
| Stockholders Equity | 722.17M | 671.64M | 442.02M | 395.06M | 187.72M |
Cash Flow | |||||
| Free Cash Flow | -276.89M | -232.83M | -185.07M | -94.64M | -54.92M |
| Operating Cash Flow | -276.39M | -232.32M | -184.17M | -93.84M | -54.58M |
| Investing Cash Flow | -37.56M | -228.65M | -94.25M | -115.13M | -74.29M |
| Financing Cash Flow | 426.74M | 457.74M | 225.67M | 322.24M | 125.28M |
Viridian Therapeutics Technical Analysis
Negative
14.47
Price Trends
27.60
Negative
29.54
Negative
24.44
Negative
Market Momentum
-3.69
Positive
20.13
Positive
4.53
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VRDN, the sentiment is Negative. The current price of 14.47 is below the 20-day moving average (MA) of 24.14, below the 50-day MA of 27.60, and below the 200-day MA of 24.44, indicating a bearish trend. The MACD of -3.69 indicates Positive momentum. The RSI at 20.13 is Positive, neither overbought nor oversold. The STOCH value of 4.53 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VRDN.
Viridian Therapeutics Risk Analysis
Viridian Therapeutics disclosed 73 risk factors in its most recent earnings report. Viridian Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Viridian Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | $4.63B | -9.59 | ― | ― | -42.64% | -39.78% | |
61 Neutral | $3.54B | -12.72 | -31.97% | ― | ― | -5.73% | |
57 Neutral | $1.77B | -7.95 | -70.76% | ― | ― | -20.08% | |
54 Neutral | $1.48B | -5.48 | -58.44% | ― | 23340.07% | 18.06% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $883.88M | -7.53 | -11.55% | ― | -23.37% | -42.45% | |
44 Neutral | $1.41B | -1.64 | -688.89% | ― | ― | 18.76% |
* Healthcare Sector Average
VRDN
Viridian Therapeutics
14.47
2.68
22.73%
DNTH
Dianthus Therapeutics
87.48
71.15
435.70%
PHVS
Pharvaris
27.56
15.26
124.07%
EWTX
Edgewise Therapeutics
33.04
20.54
164.32%
JANX
Janux Therapeutics Inc
14.53
-12.30
-45.84%
BHVN
Biohaven Ltd.
9.38
-9.29
-49.76%
Viridian Therapeutics Corporate Events
Business Operations and StrategyProduct-Related Announcements
Viridian Therapeutics Reports Positive Phase 3 REVEAL-1 Results
Positive
Mar 30, 2026
On March 30, 2026, Viridian Therapeutics reported positive topline results from its phase 3 REVEAL-1 trial of elegrobart in patients with active thyroid eye disease, positioning the drug as a potential first subcutaneous autoinjector therapy for t...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.